CEL-SCI Corporation Announces Proposed Public Offering of Common Stock and Six Month Warrants
April 11 2014 - 3:15PM
Business Wire
CEL-SCI Corporation (NYSE MKT: CVM), a late-stage
oncology company, today announced that it intends to offer and sell
common stock and six month warrants in a “best efforts”
underwritten public offering. The offering is subject to market
conditions, and there can be no assurance as to whether or when the
offering may be completed.
Dawson James Securities, Inc, and Laidlaw & Company (UK)
Ltd. are acting as joint book-running managers and underwriters for
the proposed offering.
A shelf registration statement and accompanying base prospectus
on Form S-3 relating to the securities was filed with the
Securities and Exchange Commission and is effective. The offering
may be made only by means of a prospectus, copies of which may be
obtained, when available, from the offices of Laidlaw & Company
(UK) Ltd., 546 Fifth Avenue, 5th Floor, New York, NY, 10036,
telephone: 212-953-4900, or from Dawson James Securities, 1 North
Federal Highway, Suite 500, Boca Raton, FL 33432, telephone:
561-391-5555.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any jurisdiction in which such
offer, solicitation or sale would be unlawful prior to the
registration or qualification under the securities laws of any such
jurisdiction.
About CEL-SCI Corporation
CEL-SCI is dedicated to research and development directed at
improving the treatment of cancer and other diseases by utilizing
the immune system, the body's natural defense system. Its lead
investigational therapy is Multikine (Leukocyte Interleukin,
Injection), currently being studied in a pivotal global Phase III
clinical trial. CEL-SCI is also investigating an immunotherapy
(LEAPS-H1N1-DC) as a possible treatment for H1N1 hospitalized
patients and as a vaccine (CEL-2000) for Rheumatoid Arthritis
(currently in preclinical testing) using its LEAPS technology
platform. The investigational immunotherapy LEAPS-H1N1-DC treatment
involves non-changing regions of H1N1 Pandemic Flu, Avian Flu
(H5N1), and the Spanish Flu, as CEL-SCI scientists are very
concerned about the possible emergence of a new more virulent
hybrid virus through the combination of H1N1 and Avian Flu, or
maybe Spanish Flu. The Company has operations in Vienna, Virginia,
and in/near Baltimore, Maryland.
*Multikine is the trademark that CEL-SCI has registered for this
investigational therapy, and this proprietary name is subject to
FDA review in connection with its future anticipated regulatory
submission for approval. Multikine has not been licensed or
approved for sale, barter or exchange by the FDA or any other
regulatory agency. Similarly, its safety or efficacy has not been
established for any use. Moreover, no definitive conclusions can be
drawn from the early-phase, clinical-trials data involving the
investigational therapy Multikine (Leukocyte Interleukin,
Injection). Further research is required, and early-phase clinical
trial results must be confirmed in the well-controlled, Phase III
clinical trial of this investigational therapy that is currently in
progress.
Safe Harbor Statement
When used in this release, the words "intends," "believes,"
"anticipated" and "expects" and similar expressions are intended to
identify forward-looking statements. Forward-looking statements
include, without limitation, the company’s ability to complete the
proposed public offering of its common stock and warrants described
above. Such statements are subject to risks and uncertainties which
could cause actual results to differ materially from those
projected. The Company undertakes no obligation to publicly release
the result of any revision to these forward-looking statements
which may be made to reflect the events or circumstances after the
date hereof or to reflect the occurrence of unanticipated
events.
CEL-SCI CorporationGavin de Windt, 703-506-9460
Cel Sci (AMEX:CVM)
Historical Stock Chart
From Apr 2024 to May 2024
Cel Sci (AMEX:CVM)
Historical Stock Chart
From May 2023 to May 2024